If you'd put $20,000 in this ASX healthcare stock during COVID-19, you'd have $257,000 now

You could have become filthy rich in just 4 years. Just think about that.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Of course, here at The Motley Fool we always recommend investors practise proper diversification to manage investment risk.

But there's nothing wrong with fantasising about wild riches from a single ASX stock. It's just good, clean fun.

Besides, such examples demonstrate that just one or two winners can send an entire diversified portfolio into profit by cancelling out the losers.

It's actually an advertisement for diversification.

Let's now take a look at the journey of Telix Pharmaceuticals Ltd (ASX: TLX) and how wealthy this healthcare stock could have made you by now:

What does Telix Pharmaceuticals do?

Telix Pharmaceuticals develops diagnostic and therapeutic products for different types of cancer.

When COVID-19 first spread around the globe, financial markets understandably went into meltdown.

After all, no one knew back then whether this disease would kill half the world's population or whether we'd be forced to live in lockdown forever.

In the worst depths of the market crash, in March 2020, you could buy Telix shares for 87 cents apiece.

Imagine that you had the wisdom to buy $20,000 worth at that point.

Over the next four years, you would have watched proudly as Telix Pharmaceuticals ticked off one milestone after another.

Perhaps the biggest achievement over that time was attaining commercial approval for its ​​prostate cancer imaging product Illuccix. This took Telix from a pre-revenue startup to one that makes its own money.

While Illucix is bringing in valuable revenue, Telix has been able to work on future products for other types of cancer, such as kidney, brain, and bone marrow.

The hero healthcare stock

This rapid growth and enormous future potential have forced the market to sit up and take notice of the healthcare stock.

As of Wednesday afternoon, the Telix stock price was trading at $11.19, which makes it an almost 13-bagger since you bought those 87 cent shares one Olympic cycle ago.

So that $20,000 you invested? It's now worth $257,241.

Amazing.

Check out how this one winner could have supercharged a diversified portfolio.

At the time you bought the $20,000 batch of Telix shares, say you also bought five other stocks in other industries and geographies to spread your risk.

Then imagine that those five businesses all went through absolute devastation and have now shrunk to $0.

That portfolio would now be more than double what the original $120,000 outlay.

Ladies and gentlemen, right there is the power of ASX shares and diversification.

Motley Fool contributor Tony Yoo has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

3 children standing on podiums wearing Olympic medals
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rather woeful Wednesday session for the ASX today.

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Share Gainers

Why 4DMedical, Megaport, Meteoric Resources, and Ramelius shares are racing higher today

These shares are having a good session on hump day. But why?

Read more »

Winning woman smiles and holds big cup while losing woman looks unhappy with small cup
Share Gainers

Here are the top 10 ASX 200 shares today

It was a dour Tuesday for ASX investors.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Brightstar Resources, Immutep, Pilbara Minerals, and Race Oncology shares are roaring higher

These shares are having a strong session on Tuesday. But why?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a Garfield kind of Monday for investors.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today

These shares are starting the week in a positive fashion. But why?

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »